Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SINTART2: Multimodality Treatment for Inoperable Sinonasal Tumors
NCT02099188Phase 2Unknown
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Nov 2013
- Primary completion
- Jun 2020
- Modality
- Targeted Liposomes, Orthosteric Ligands, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of Cisplatin micelle injection (HA132), docetaxel, fluorouracil, etoposide, pegylated liposomal doxorubicin in sinonasal tumor, sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Status: unknown.
02
Drugs
Cisplatin micelle injection (HA132)docetaxelfluorouraciletoposidepegylated liposomal doxorubicin
03
Conditions
sinonasal tumor
Beyond the preview
Go deeper on NCT02099188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02099188.